KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EBT: 2009-2024

Historic EBT for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$176.6 million.

  • Novavax's EBT fell 65.97% to -$203.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.7 million, marking a year-over-year increase of 225.36%. This contributed to the annual value of -$176.6 million for FY2024, which is 67.48% up from last year.
  • Novavax's EBT amounted to -$176.6 million in FY2024, which was up 67.48% from -$543.0 million recorded in FY2023.
  • Novavax's 5-year EBT high stood at -$176.6 million for FY2024, and its period low was -$1.7 billion during FY2021.
  • In the last 3 years, Novavax's EBT had a median value of -$543.0 million in 2023 and averaged -$457.8 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 309.92% in 2021, then skyrocketed by 67.48% in 2024.
  • Over the past 5 years, Novavax's EBT (Yearly) stood at -$418.3 million in 2020, then crashed by 309.92% to -$1.7 billion in 2021, then skyrocketed by 61.88% to -$653.6 million in 2022, then climbed by 16.92% to -$543.0 million in 2023, then spiked by 67.48% to -$176.6 million in 2024.